Prosthetic Joint Infection Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Prosthetic Joint Infection Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of PJI, historical and forecasted epidemiology, as well as the PJI market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Prosthetic Joint Infection Market with DelveInsight's In-Depth Report @ Prosthetic Joint Infection Market Size [https://www.delveinsight.com/sample-request/prosthetic-joint-infection-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Prosthetic Joint Infection Market Report

* In October 2024:- Trellis Biosciences Inc.- This Phase 2 study is designed to assess efficacy and safety of TRL1068 in combination with a DAIR (debridement, antibiotics, and implant retention) procedure for chronic prosthetic joint infections of the knee and hip, specifically, eliminating the need for the standard of care 2-stage exchange surgery, so that the original prosthesis can be retained.
* According to DelveInsight's epidemiology model, in the 7MM, the total cases of PJI were approximately 89,176 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by the aging population, along with increased joint replacement surgeries.
* In 2023, the US reported the highest number of PJI cases, totaling around 56,077, whereas Japan reported the fewest, with approximately 2,741 cases.
* Among EU4 and the UK, Germany reported the highest number of PJI cases in 2023, with approximately 13,469 cases. Italy followed with around 5,355 cases, and the UK had nearly 4,599 cases.
* In Japan in 2023, gender-specific cases of PJI included approximately 1,491 cases in males and 1,250 cases in females.
* In 2023, Japan recorded approximately 1,919 cases of PJI caused by gram-positive bacteria, compared to 699 cases attributed to gram-negative bacteria.
* The leading Prosthetic Joint Infection Companies such as Arrevus, TenNor Therapeutics, Peptilogics, and others.
* Promising Prosthetic Joint Infection Therapies such as TRL1068, VT-X7 Treatment System, 0.9% NaCl solution, and others.

Stay ahead in the Prosthetic Joint Infection Therapeutics Market with DelveInsight's Strategic Report @ Prosthetic Joint Infection Market Outlook [https://www.delveinsight.com/sample-request/prosthetic-joint-infection-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Prosthetic Joint Infection Epidemiology

* Total number of arthroplasty cases
* Total Cases of Prosthetic Joint Infection
* Gender-specific cases of Prosthetic Joint Infection
* Causative microorganism-specific cases

Download the report to understand which factors are driving Prosthetic Joint Infection epidemiology trends @ Prosthetic Joint Infection Prevalence [https://www.delveinsight.com/sample-request/prosthetic-joint-infection-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Prosthetic Joint Infection Emerging Drugs

* VT-X7 (vancomycin hydrochloride and tobramycin sulfate): Osteal Therapeutics

VT-X7 is an advanced drug/device combination product developed by Osteal Therapeutics, specifically designed to deliver therapeutic concentrations of vancomycin hydrochloride and tobramycin sulfate directly to the joint space for the treatment of PJI.

This innovative seven-day therapy addresses the critical need for rapid and effective treatment of PJI, demonstrating significant clinical efficacy in a Phase II study, where 100% of patients received a new permanent joint prosthesis within seven days, with 93% remaining infection-free at one year. The US FDA has recognized VT-X7's potential by granting it Breakthrough Therapy Designation, alongside orphan drug, fast track, priority review, and Qualified Infectious Disease Product designations.

* PLG0206: Peptilogics

PLG0206 is an innovative investigational therapeutic peptide developed by Peptilogics for the treatment of PJI. With a unique mechanism of action that disrupts bacterial membranes, PLG0206 effectively targets persistent pathogens within biofilms that evade standard antibiotic treatments. The US FDA has granted PLG0206 Orphan Drug Designation, Qualified Infectious Disease Product (QIDP) status, and Fast Track Designation, underscoring its therapeutic potential.

Recent interim data from the ongoing Phase Ib trial demonstrated a favorable safety profile, with no treatment-related serious adverse events reported and a low recurrence rate of 7% in the Low Dose cohort at Day 180, while the High Dose cohort showed no recurrences. These findings highlight PLG0206's promising role in addressing the significant clinical challenge posed by PJI.

Prosthetic Joint Infection Treatment Market

The Prosthetic Joint Infection treatment necessitates a multifaceted approach combining surgical and antimicrobial strategies tailored to the specific pathogens involved. Surgical interventions may include open or arthroscopic debridement, prosthesis resection, or, in some cases, revision surgery, ideally conducted alongside pathogen-directed antimicrobial therapy. Antimicrobial regimens prioritize the use of narrow-spectrum antibiotics, such as cefazolin, rifampicin, and vancomycin, while companion drugs are essential for preventing resistance, particularly with Staphylococcal infections.

Get In-Depth Knowledge on Prosthetic Joint Infection Market Trends and Forecasts with DelveInsight @ Prosthetic Joint Infection Treatment Market [https://www.delveinsight.com/sample-request/prosthetic-joint-infection-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Prosthetic Joint Infection Market Outlook

The treatment landscape for PJI necessitates a multifaceted approach combining medical and surgical strategies, driven by the imperative for individualized and effective antimicrobial therapies. Current regimens primarily involve well-established antibiotics such as cefazolin, rifampicin, and vancomycin, which must be tailored based on pathogen susceptibility profiles. Notably, rifampicin's efficacy against Staphylococcal biofilms underscores the need for combination therapy to mitigate rapid resistance development.

Scope of the Prosthetic Joint Infection Market Report

* Coverage- 7MM
* Prosthetic Joint Infection Companies- Arrevus, TenNor Therapeutics, Peptilogics, and others.
* Prosthetic Joint Infection Therapies- TRL1068, VT-X7 Treatment System, 0.9% NaCl solution, and others.
* Prosthetic Joint Infection Therapeutic Assessment: Prosthetic Joint Infection Current marketed and Influenza A Infections emerging therapies
* Prosthetic Joint Infection Market Dynamics: Prosthetic Joint Infection Market drivers and Prosthetic Joint Infection Market Barriers

Unlock Strategic Insights with DelveInsight's Comprehensive Prosthetic Joint Infection Market Report @ Prosthetic Joint Infection Market Drivers and Barriers [https://www.delveinsight.com/sample-request/prosthetic-joint-infection-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1 Key Insights

2 Report Introduction

3 Executive summary

4 Epidemiology and Market Methodology

5 Market Overview at a Glance

6 Key Events

7 Disease Background and Overview

8 Patient Journey

9 Epidemiology and Patient Population

10 Emerging Therapies

11 PJI: Market Analysis

12 Key Opinion Leaders' Views

13 SWOT Analysis

14 Unmet Needs

15 Market Access and Reimbursement

16 Appendix

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=prosthetic-joint-infection-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity



This release was published on openPR.